In our study, we want to show the effect of prophylactic G-CSF on infection frequency, neutrophil and platelet engraftment, the duration of neutropenia, the development of GVHD, hospital stay, and transplant-related mortality (TRM) after ASCT. This evidence concerns the gene CSF3 and graft versus host disease.